Abstract:Introduction: TrialNet TN07, a randomized controlled trial, assessed oral insulin for preventing type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D. Of 560 participants, the stratum characterized by low first-phase insulin release (LFIR) (n=57) showed a positive response to oral insulin, while others (n=503) did not. We aimed to understand genetic differences between participants with and without LFIR, and between responders and non-responders to oral insulin in the LFIR stratum. Methods: 552 participants were genotyped using the TEDDY T1DExome array. We compared T1D and insulin associated single nucleotide polymorphisms (SNPs), human leukocyte antigen (HLA) alleles, and T1D genetic risk scores (T1DGRS) in the LFIR stratum vs others using Fisher's tests and t tests. In the LFIR stratum, we used Cox models to examine genetic factors that identify participants with slower T1D progression in response to treatment. Results: Participants with LFIR had higher T1DGRS than those without LFIR (mean 14.2 vs 13.7, p=0.04); higher frequencies of INS rs1004446 susceptible allele (63% vs 48%, p=0.04), higher frequencies of homozygosity for IL27 rs4788084 susceptible allele (18% vs 7%, p=0.04), and lower frequencies of the HLA DRB1*13/DQA1*01 protective haplotype (5% vs 17%, p=0.02). In participants with LFIR, hazard ratio (HR) of response to oral insulin treatment compared to placebo was different in participants with vs without GLIS3 rs7020673 protective allele (respectively, HR: 0.90 vs 0.08, p=0.003), with vs without PXK/PDHB rs11705721 susceptible allele (HR: 0.26 vs 1.09, p=0.05) and with vs without the HLA DRB1*0401/DQA1*0301 susceptible haplotype (HR: 0.23 vs 1.36, p=0.01). Conclusion: Genetic differences exist in autoantibody-positive relatives with and without LFIR, and in LFIR stratum, between responders and non-responders to oral insulin for T1D prevention. Genetics may help precision medicine by identifying candidates responsive to T1D-modifying therapies. Disclosure L. You: None. H.M. Parikh: None. T.M. Triolo: None. L.A. Ferrat: Consultant; Johnson & Johnson Medical Devices Companies. E. Templeman: None. R.A. Oram: Research Support; Randox R & D. Consultant; Provention Bio, Inc., Sanofi. P. Gottlieb: Other Relationship; IM Therapeutics. Research Support; Imcyse. Advisory Panel; Imcyse. Consultant; Juvenile Diabetes Research Foundation (JDRF). Research Support; Hemsley Charitable Trust, Novartis AG, Provention Bio, Inc., Precigen, Inc. Advisory Panel; ViaCyte, Inc. Research Support; Nova Pharmaceuticals. S.S. Rich: None. S. Onengut-Gumuscu: None. A. Steck: None. J. Krischer: None. M.J. Redondo: None. Funding This research was funded by the National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK121843). The Type 1 Diabetes TrialNet Study Group is a clinical trials network currently funded by the National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, and The Eunice Kennedy Shriver National Institute of Child Health and Human Development, through the cooperative agreements U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085461, U01 DK085465, U01 DK085466, U01 DK085476, U01 DK085499, U01 DK085509, U01 DK103180, U01 DK103153, U01 DK103266, U01 DK103282, U01 DK106984, U01 DK106994, U01 DK107013, U01 DK107014, UC4 DK106993, UC4DK117009, and the JDRF.

A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab

Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial

First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes: an exploratory analysis of immune biomarkers

Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 Diabetes

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes

Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes

Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes

Two First-in-human Studies of Xentuzumab, a Humanised Insulin-Like Growth Factor (Igf)-Neutralising Antibody, in Patients with Advanced Solid Tumours.

Islet Autoimmunity in Adults With Impaired Glucose Tolerance and Recently Diagnosed, Treatment Naïve Type 2 Diabetes in the Restoring Insulin SEcretion (RISE) Study

855-P: Evolution of KT-A112, an AAV-Mediated Gene Therapy for the Treatment of Type 1 Diabetes

Intestinal Delivery of Proinsulin and IL-10 via Lactococcus lactis Combined With Low-Dose Anti-CD3 Restores Tolerance Outside the Window of Acute Type 1 Diabetes Diagnosis

Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol

Phase 3 trial of human islet‐after‐kidney transplantation in type 1 diabetes

154-OR: Genetic Predictors of Response to Oral Insulin for Type 1 Diabetes Prevention

A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes

Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol

A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes

Investigating the effect of verapamil on preservation of beta-cell function in adults with newly diagnosed type 1 diabetes mellitus (Ver-A-T1D): protocol for a randomised, double-blind, placebo-controlled, parallel-group, multicentre trial

Pre-clinical development of a tolerogenic peptide from glutamate decarboxylase as a candidate for antigen-specific immunotherapy in type 1 diabetes

An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetes